The rehabilitation room at a German neurological clinic looks different these days. Where patients once worked through paper worksheets with therapists hovering nearby, many now interact with an app that corrects their speech in real time, adjusts cognitive exercises on the fly, and logs every incremental gain. The shift has been gradual—perhaps more gradual than entrepreneurs hoped—but it's accelerating.
Nyra Health, the Vienna-based startup behind much of this change, has just raised €20 million in Series A funding to push further. Armira Growth, a Munich firm with a relatively new €200 million fund, led the round announced February 24. Wellington Partners, Crane Venture Partners (which now manages what used to be MassMutual Ventures' European and Asia-Pacific portfolios), and EVER Pharma came in alongside them.
The timing isn't accidental. Nyra has reached a kind of tipping point: more than 100 neurological clinics across German-speaking Europe now use its tools, giving access to roughly 40 million people insured through partner health plans in Germany. That's the sort of scale that separates hopeful pilots from entrenched infrastructure.
From Medical Frustration to Market Entry
Moritz Schöllauf, the CEO, co-founded Nyra with his brother Dr. Philipp Schöllauf, the chief scientific officer, and Mario Zusag, who runs technology. The company pulled in €2.2 million in pre-seed capital back in December 2021, then €4.5 million more in a June 2023 seed round. This latest injection—nearly five times the seed total—reflects both investor appetite for digital health and, crucially, evidence that German insurers are willing to reimburse.
That last point matters enormously. European digital health startups often stumble not on product development but on reimbursement negotiations—a labyrinthine process that can take years and drain capital. Nyra, though, has secured direct partnerships with heavyweights like Techniker Krankenkasse, Germany's largest public health insurer, which now covers six months of app access for eligible members. SIGNAL IDUNA, another major insurer, has also signed on.
As of January 1, 2025, Nyra's flagship app, myReha, became part of Germany's DRV digital IRENA aftercare program. For clinics, this means they can transition recovering patients seamlessly from inpatient care to reimbursed at-home digital therapy—no paperwork purgatory, no coverage denials.
The Product Suite: AI Meets Aphasia
myReha is Nyra's core offering: a CE-marked (European regulatory approval) therapy app designed for patients recovering from stroke, traumatic brain injury, or neurodegenerative diseases. It targets speech, language, and cognitive rehabilitation—areas where traditional therapy is both expensive and unevenly accessible outside major cities.
The AI component isn't flashy in the Silicon Valley sense. It doesn't generate art or write poetry. Instead, it listens to a patient's slurred consonants, watches how they sequence tasks, and adjusts difficulty in real time. Feedback comes immediately, not days later in a therapist's notes. Patients work through exercises at home, in clinics, or during outpatient visits, with progress syncing to a dashboard therapists monitor remotely.
Nyra also sells nyra insights, an analytics and patient management tool for clinics—essentially the back-end infrastructure that helps providers track outcomes, schedule interventions, and justify reimbursement claims. A third product, Content Studio, is listed as "coming soon" on the company's site. It's supposed to use AI to generate new therapy materials, though details remain sparse.
Chasing Scale Across Borders
The fresh capital will fund expansion deeper into the DACH region (Germany, Austria, Switzerland), with Nyra aiming to sign more clinics and broaden insurer partnerships. But the company also has its sights on the United States, in collaboration with an unnamed international pharmaceutical partner. That's a bold move. The U.S. healthcare market is notoriously fragmented, and reimbursement pathways differ wildly by state and payer. Still, the sheer size of the market makes it irresistible.
Nyra also plans to pour money into what it calls "multimodal AI models" for therapeutic interaction and diagnostics. Coverage of the funding announcement references a €4.2 million research initiative with U.S. universities, though independent verification of that specific grant wasn't immediately available.
Armira Growth, which closed its debut fund in May 2024, has recently backed growth-stage European B2B software and healthcare technology firms. Its portfolio includes FTAPI, which raised €65 million in February 2025, and AVILOO Diagnostics, which secured roughly €30 million in February 2026 (though that date appears to be a typo or projection).
A Market with Room—and Competition
The digital neurological rehabilitation space has drawn investor attention for good reason. Neurological diseases cost Germany's health system more than €60 billion annually, according to health economists. Stroke alone affects hundreds of thousands of Europeans each year, many of whom need months or years of therapy.
Competitors are circling. UK-based Strolll raised €12.2 million in March 2025 for augmented-reality neurorehab software. Swiss incumbent MindMaze, which has been in the field longer, pulled in $105 million back in 2022. Both are chasing similar problems: How do you deliver consistent, high-quality therapy when therapists are scarce and patients are scattered?
Nyra's bet is that reimbursement partnerships—not just product elegance—will determine winners. The company has moved faster than most on that front, locking in German insurers before many rivals even began regulatory filings. Whether that head start translates to durable advantage remains to be seen. But for now, at least, Nyra has both the capital and the clinic footprint to find out.
---
This article is based on public disclosures, company announcements, and available investment data. Some figures, particularly regarding future projections and research grants, could not be independently verified at the time of publication.
